Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Published: 2026-04-24 16:05:12 ET NTLA

Published on 04/24/2026 at 04:05 pm EDT

CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website at intelliatx.com. A replay of the webcast will be available for approximately 90 days.

About Intellia TherapeuticsIntellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:Jason FredetteVice President, Investor Relations and Corporate CommunicationsIntellia Therapeutics, [email protected]

Media Contact:Mike TattoryVice PresidentLifeSci [email protected]

2026 GlobeNewswire, Inc., source Press Releases